Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ERSP refers Moxxor, Siglas to FTC

This article was originally published in The Tan Sheet

Executive Summary

The Electronic Retailing Self-Regulation Program refers Moxxor, the omega-3 dietary supplement, to the Federal Trade Commission after the product's manufacturer of the same name failed to respond to an inquiry about its product, ERSP says Oct. 27. ERSP conducted a review of the firm's online advertising after receiving an anonymous complaint, and later requested substantiation for performance, endorsement, superiority and testimonial claims. ERSP also refers Siglas Inc. to the FTC for not substantiating performance and exclusivity claims for the Sauna Twin Multi-Lipo Reductor. Siglas failed to submit a "substantive response" to ERSP despite multiple requests and a 10-day deadline extension, ERSP said in a separate Oct. 27 release

You may also be interested in...



EU Regulatory Round-Up, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty

Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.

Emerging Markets Help Fresenius Kabi Offset US Pressures

Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.

Fresenius Kabi And Vifor Ally In China

Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.

Topics

UsernamePublicRestriction

Register

PS103474

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel